tbuckley/cabot-search huggingface dataset:
AB0073 ANTI-ARTHRITIC ACTIVITIES OF THE ELEUTHEROCOCCUS SENTICOSUS, ACHYRANTHES JAPONICA, AND ATRACTYLODES JAPONICA MIXED EXTRACT FERMENTED WITH NURUK IN A TYPE II COLLAGEN-INDUCED ARTHRITIS MOUSE MODEL
Authors: C. H. Lee, C. H. Chung, W. H. Yoo, Y. Choi, M. S. Lee
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Rheumatoid arthritis (RA) is an autoimmune disease that is accompanied by chronic synovitis, progressive cartilage, and bone destruction and is affected by inflammatory-associated factors. Vigeo is a mixture of fermented extracts of <i>Eleutherococcus senticosus</i> Maxim (ESM), <i>Achyranthes japonica</i> (Miq.) Nakai (AJN), and <i>Atractylodes japonica</i> Koidzumi (AJK) manufactured using the traditional Korean nuruk fermentation method. Although the bioactive effects of ESM, AJN, and AJK have already been reported, the pharmacological effects of Vigeo have not been proven. <h3>Objectives</h3> In this study, we investigated whether Vigeo had inhibitory effects on RA and its intracellular mechanisms using a type II collagen-induced arthritis (CIA) mouse model. <h3>Methods</h3> CIA was induced in DBA/1 mice by immunization with bovine type II collagen. The mice were administered orally with Vigeo (200 and 500 mg/kg/day, i.g.) from days 21 to 42 after immunization. The clinical scores, hind paw swelling, and histopathological finding were evaluated in the paw of CIA mice. The levels of tumor necrosis factor α (TNF-α), interleukin (IL)-6, and IL-1β in the serum were measured by enzyme-linked immunosorbent assay. <h3>Results</h3> The results showed that Vigeo 500 mg/kg treatment significantly alleviated the severity of the disease, based on the reduced hind paw swelling and clinical scores, compared with untreated CIA mice. Comparing with untreated CIA mice, Vigeo 500 mg/kg treatment inhibited the levels of TNF-α, IL-6, and IL-1β in the serum. <h3>Conclusion</h3> Our results suggest that anti-inflammatory effects of Vigeo against collagen-induced arthritis in mice may be due to its ability to inhibit pro-inflammatory mediators. Vigeo may be a promising potential therapeutic reagent for arthritis treatment. <h3>References</h3> [1]Rousseau, S.; Kyomugasho, C.; Celus, M.; Hendrickx, M.E.G.; Grauwet, T. Barriers impairing mineral bioaccessibility and bioavailability in plant-based foods and the perspectives for food processing. <i>Crit. Rev. Food Sci. Nutr.</i><b>2020</b>, <i>60</i>, 826–843 [2]Cheon, Y.H.; Baek, J.M.; Park, S.H.; Ahn, S.J.; Lee, M.S.; Oh, J.M.; Kim, J.Y. <i>Stauntonia hexaphylla</i> (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression. <i>BMC Complementary Altern. Med.</i><b>2015</b>, <i>15</i>, 280 [3]Hwang, Y.C.; Jeong, I.K.; Ahn, K.J.; Chung, H.Y. The effects of <i>Acanthopanax senticosus</i> extract on bone turnover and bone mineral density in Korean postmenopausal women. <i>J. Bone Miner. Metab.</i><b>2009</b>, <i>27</i>, 584–590 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1029 THE RELATIONSHIP BETWEEN THE PRESENCE OF ISCHIAL ENTHESITIS AND OTHER RADIOLOGICAL INVOLVEMENTS AND PERIPHERAL ENTHESITIS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Authors: E. Durak Ediboglu, A. Sinci, D. Solmaz, E. Erpek, H. Cinakli, G. Alp, E. Otman Akat, İ. Kurut Aysin, A. Özkan, H. Kocaayan, S. Gucenmez, M. Ozmen, S. Akar
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Sacroiliac radiographs in axial spondyloarthritis (axSpA) allow the evaluation of sacroiliac and hip joint involvement, as well as the symphysis region and ischial enthesis regions. In this study. <h3>Objectives</h3> It is planned to test and review the relationship between the presence of ischial enthesitis and disease-related factors, the presence of peripheral enthesitis and other radiological features of involvement. <h3>Methods</h3> Of 355 patients with axSpA diagnosis and follow-up sacroiliac joint radiography evaluated for ischial enthesitis were included in the study. Since the presence of ischial enthesitis was detected in 1 patient in non-radiographic axSpA patients, the analysis was performed with radiographic axSpA patients. Demographic, clinical and laboratory characteristics of the patients were recorded. Irregular appearance in the region where tendons and ligaments attach to the bone (lower region) in the pubic arms in the sacroiliac joint X-ray was evaluated as ischial enthesitis. Radiological evaluation was performed by a rheumatologist (EDE) and a radiologist (AS). The relationship between the presence of ischial enthesitis and other factors was tested with both univariate and multivariate analysis methods. <h3>Results</h3> The mean age at diagnosis (±SD) was 42 (11.9) and 74% of the patients included in the study were male. Demographic and radiological characteristics of the study group are summarized in Table 1. Ischial enthesitis was detected in 57 (16.1%) patients. Gender (p=0.006), symptom duration (p&lt;0.001), duration of diagnosis (p=0.002), HLA-B27 positivity (p=0.09), radiographic hip involvement (p=0.09) total sacroiliac joint score (p&lt;0.001), baseline cervical mSASS score (p&lt;0.001), basal lumbar mSASS score (p&lt;0.001), presence of symphysis (p&lt;0.001), serum CRP level (p=0.014) found to be associated with ischial enthesitis in univariate analysis. There was no correlation between the presence of ischial enthesitis and heel pain (p=0.61) or SPARCC enthesitis score (p=0.59). In the two models established in the multivariate analysis, serum CRP level (p=0.022), presence of cervical syndesmophyte (p=0.042), presence of total ankylosis in the sacroiliac joint (p=0.012) and SIE score (p=0.001) were found to be independent variables associated with the presence of ischial enthesis. <h3>Conclusion</h3> Although ischial enthesitis can be seen independently of clinical heel pain in axSpA patients, it can also be an indicator of radiographic damage. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1051 PREGNANCY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Authors: S. Gore, R. Tambe, N. Sunil, A. Raut, P. Patil
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> There is limited information available on the course of axial spondyloarthritis (AxSpA) during pregnancy, in contrast to other chronic inflammatory disorders. AxSpA poses a special set of challenges because it has anatomical and inflammatory consequences on pregnancy. <h3>Objectives</h3> The aim of this study was to evaluate the course of AxSpA during pregnancy. <h3>Methods</h3> In order to evaluate the course of AxSpA during pregnancy, an observational descriptive retrospective study was carried out at a private rheumatology clinic. Data were gathered using a self-administered questionnaire from 70 women who were diagnosed with AxSpA prior to pregnancy. <h3>Results</h3> The average age at disease onset was 23.6 years. Approximately one-third (35.7%) of patients said their AxSpA symptoms were worse during pregnancy, compared to 64.2% who said their symptoms got better. The postpartum flare was reported by 52.5% women. The mode of delivery was by cesarean section in 76% patients. Back pain and stiffness during pregnancy were the most prevalent symptoms. None of the patients had extra-articular manifestations during pregnancy or postpartum. Adverse pregnancy outcomes were reported by 15.7% patients. In our study, we found that the majority of women avoided using drugs even when they felt the need to do so out of concern for the foetus. <h3>Conclusion</h3> A large number of patients reported ease of symptoms during pregnancy. Due to the significant risk of flare, patients should be followed up during post-partum period. AxSpA females have an increased prevalence of cesarean sections. <h3>References</h3> [1]Lui NL, Haroon N, Carty A, Shen H, Cook RJ, Shanmugarajah S, Gladman DD, Inman RD (2011) Effect of pregnancy on ankylosing spondylitis: a case-control study. J Rheumatol 38(11):2442–2444. [2]Park EH, Lee JS, Kim YJ, Lee SM, Jun JK, Lee EB, Kim YG (2019) Pregnancy outcomes in Korean women with ankylosing spondylitis. Korean J Intern Med 26. [3]Mokbel A, Lawson DO, Farrokhyar F. Pregnancy outcomes in women with ankylosing spondylitis: a scoping literature and methodological review. Clin Rheumatol. 2021 Sep;40(9):3465-3480. doi: 10.1007/s10067-021-05588-9. Epub 2021 Jan 19. PMID: 33464430. [4]Singh, Neetu; Pradeep, Yasodhara; Jauhari, Sugandha<sup>1</sup>. Indications and Determinants of Cesarean Section: A Cross-Sectional Study. International Journal of Applied and Basic Medical Research 10(4):280-285, Oct–Dec 2020. | DOI: 10.4103/ijabmr.IJABMR_3_20 [5]Sinead Maguire, Tom O'Dwyer, David Mockler, Finbar O'Shea, Fiona Wilson,Pregnancy in axial spondyloarthropathy: A systematic review &amp; meta-analysis,Seminars in Arthritis and Rheumatism,Volume 50, Issue 6,2020. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0523 TOXIC EPIDERMAL NECROLYSIS(TEN) IN SYSTEMIC LUPUS ERYTHEMATOSUS(SLE): RESULTS FROM A MULTI-INSTITUTIONAL COHORT FROM INDIA
Authors: K. Chandwar, A. Jain, P. Ghosh, A. Balakrishnan, S. Manuel, S. Mukherjee, A. Paruthi, P. Srivastava, A. Singh, A. Wakhlu
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Toxic Epidermal Necrolysis(TEN) is a rare but life-threatening manifestation of Systemic Lupus Erythematosus (SLE). Epidermal necrolysis (EN), including Stevens–Johnson syndrome and TEN, is commonly drug induced. Furthermore, flares of SLE may present as EN (TEN-like LE). To the best of our knowledge, this is the largest series of SLE-TEN. <h3>Objectives</h3> The current study aimed to study the clinical characteristics and outcome of SLE-related TEN in the Indian population. <h3>Methods</h3> All patients satisfying ACR/EULAR 2019 criteria for SLE and clinically diagnosed with TEN were retrospectively reviewed and compiled from 7 rheumatology centres across India. Drug-induced TEN were excluded from the analysis. <h3>Results</h3> 16 patients (1 child) were included in the study. The majority of patients were females (13/81.25%). The median age of presentation was 25 (8-50) years, and one-third of patients (5/31.5%) presented with TEN as one of their first manifestations. All patients of TEN had active lupus in more than one domain (Median SLEDAI, 20.5). Involvement of constitutional domain followed by hematological was most common (Figure 1). Involvement of other domains is described in Figure 1. Most patients had low complements (14/87.5%), positive anti-dsDNA (13/81.25%) and anti-SSA positivity (12/75%). Management was dictated by activity in various domains and all patients had received steroids (1mg/kg in 13 and 0.5mg/kg in 3). Half of them received intravenous (IV) pulse steroid therapy and one-fourth were administered IV Immunoglobulins (IVIG). All but one patient were put on a steroid-sparing agent (Table 1). Outcomes were good, with all patients recovering from the TEN episode. Two patients who were lost to follow up, had died at their home and exact cause of death could not be ascertained. <h3>Conclusion</h3> TEN was a presenting manifestation in one-third of the patients with active disease in more than one domain. More than half of the patients had renal involvement and a quarter had Neuropsychiatric lupus (NPSLE). Anti- dsDNA, Anti-SSA positivity and low complements were common in patients with SLE-TEN. All patients required high-dose steroids for acute management of TEN, with maintenance therapy being guided by other domains involved. Though IVIG is often mentioned in literature as the treatment of choice for TEN, Most patients with SLE-TEN did well with pulse and oral Steroids suggesting IVIG could be reserved for patients with severe, resistant disease or in patients with concomitant sepsis. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0244 ROLE OF FATIGUE IN DIFFICULT TO TREAT RHEUMATOID ARTHRITIS PATIENTS OUTCOME
Authors: J. P. Otazu Moudelle, D. Freites, M. Rodríguez Laguna, C. Hormigos, M. P. Álvarez Hernandez, A. Madrid García, L. Abasolo, L. León
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In difficult to treat rheumatoid arthritis patients (D2T RA), a wide spectrum of factors may contribute to the persistence of signs and/or symptoms, although these are not always directly related to inflammation (eg, functional disability, pain and fatigue). Of these, fatigue is still the least evaluated and taken into account. <h3>Objectives</h3> To identify the role of fatigue in D2T RA. <h3>Methods</h3> Cross-sectional study. 143 patients patients followed up in the rheumatology outpatient clinic of Hospital Clínico San Carlos, Madrid, Spain were included. Data were collected between July 2018 and November 2022. All patients met the ACR/EULAR 2010 criteria and they were in treatment with Biological agents (anti-TNF and Non anti-TNF) or Targeted Synthetic DMARDs (jakinibs). D2T RA was defined based on EULAR criteria (treatment failure, signs suggestive of currently active/progressive disease, and management being perceived as problematic by the rheumatologist and/or patient). Main variable: Fatigue was assessed by the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ). Covariables: Sociodemographic and disease-related variables. Statistical analysis. A descriptive and comparative analysis was carried out for the different variables. To identify factors independently associated to D2T RA a multivariable logistic regression was applied. Results were expressed as OR with their corresponding 95% CI. A value of p &lt; 0.05 was consider as statistically significant. <h3>Results</h3> The study population comprised 143 patients and 22 (15.38%%) developed D2T RA. The D2T RA group were older, with a higher DAS28 and disability. Sociodemographic, clinical, disease-related variables, and the fatigue scores used in the study are shown in Table 1. In our final logistic regression model, age (OR: 1.05; p=0.017) and fatigue were independently associated with D2T RA (OR: 1.04; p=0.011). <h3>Conclusion</h3> Despite the absence of an explicit mention of fatigue in the definition of AR D2T, it appear to be a main factor explaining the D2T RA outcome. The evaluation and management of fatigue should be one of the objectives in the treatment of patients with RA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0466 IDENTIFICATION OF POTENTIAL BLOOD BIOMARKERS FOR JAK INHIBITOR TREATMENT-RELATED PATHWAYS THROUGH BULK RNA SEQUENCING ANALYSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: H. H. Chen, T. M. Ko
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Targeted small molecule therapy that inhibits receptor-mediated signaling via Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathways has become an established strategy for the treatment of rheumatoid arthritis (RA). The rationale for using these inhibitors is that JAKs have critical roles in specific pathological mechanisms and thus their targeted inhibition can lead to effective disease control. Despite JAK inhibitors (JAKi) having been approved for the treatment of RA and other systemic or organ-specific autoimmune diseases, the DAS28 response to JAKi is highly variable, emphasizing the need for reliable biomarkers. <h3>Objectives</h3> To reveal the potential impact of JAKi on treating RA patients, we aim to identify the biomarkers related to the responses of JAKi from blood bulk RNA-seq. <h3>Methods</h3> To better understand the molecular mechanisms of JAKi, we analyzed the global transcriptomics profile (using bulk RNA-seq) in peripheral blood mononuclear cells (PBMCs) that were collected from three RA patients before and after the treatment of JAKi. <h3>Results</h3> Comparing the responder and non-responder groups, we identified 1366 upregulated differentially expressed genes (DEGs) and 1366 upregulated differentially expressed genes (DEGs), and 1630 DEGs. To reveal further insight into the biological roles of the DEGs, we performed GO pathway analysis. Compared with responders, we found that the non-responders have a higher inflammation rate. In addition, non-responders have higher expression of genes that are involved in the JAKs signaling pathway. Specifically, gene profiling of non-responder represents higher Type I and II interferon pathway. In contrast, gene profiling of the responder represents a higher IL-12 pathway. <h3>Conclusion</h3> These changes were accompanied by changes in broader immune cell composition, based on the deconvolution of bulk RNA-sequencing data. In summary, our study revealed several phenotypic and cellular changes that underlie the clinical improvement with JAKi. <h3>Reference</h3> [1]Henkel M DF, Jones DM, Wilkerson ER, Horne W, Kolls JK, et al. RNA transcripts from peripheral blood mononuclear cells as predictors of clinical responsiveness in rheumatoid arthritis subjects treated with abatacept. Arthritis and rheumatism. 2013;65 Suppl 10:1485. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB0934 SYSTEMIC SCLERODERMA IN MEN: A CASE REPORT OF 10 PATIENTS
Authors: A. Taouch, W. Ammouri, F. Ibourk el Idrissi, W. Chawad, N. Mouatassim, H. Khibri, M. Maamar, H. Harmouche, Z. Tazi Mezalek, M. Adnaoui
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Systemic scleroderma is a connective tissue disease that is common in women and characterized by vascular alterations associated with skin fibrosis and visceral manifestations. Several particularities of this connectivitis in men are discussed. We propose to show these particularities in men through 10 cases. <h3>Objectives:</h3> <h3>Methods</h3> We identified 10 cases of systemic scleroderma in men among 60 cases of systemic scleroderma collected for our descriptive restrospective study in the internal medicine department of the IBN SINA University Hospital in Rabat. The search for clinical or subclinical visceral involvement was performed in all our patients. <h3>Results</h3> The average age of the patients was 61 ±14.1 years (extremes: 28-74 years) with a delay in diagnosis of 8 months. General signs were found in 3 patients (30%), the skin involvement was made of diffuse sclerosis in 6 cases (60%) and limited in 4 cases (40%); Raynaud's phenomenon was noted in 7 cases (70%). Pulpal ischemia and digital ulcer were noted in 1 and 3 cases respectively. Telangiectasias in 1 case. Joint involvement was present in half of the cases. Pulmonary involvement was present in 6 cases (60%). Pulmonary fibrosis was found in 1 case. Cardiac involvement was found in 6 cases (60%), of which 4 cases had PAH, one case of pericarditis and one case of heart failure. Esophageal involvement was found in 4 cases (40%). Biologically, an inflammatory syndrome was noted in 4 patients (40%). Antinuclear antibodies were positive in 7 cases (70%). Anti-Scl70 was detected in 4 cases (40%). Capillaroscopy showed lesions suggestive of organic microangiopathy in 2 cases (20%). 4 of our patients were treated with colchicine. Corticosteroids were prescribed in 2 cases. Half of our patients received immunosuppressive treatment, including 3 cases who received monthly courses of cyclophosphamides with relay by Imurel, and 3 patients received treatment by mycophenolate mofetil, stopped in one patient due to hepatic cholestasis. The association with autoimmune diseases was noted in 2 patients, including one with rheumatoid arthritis and one with primary biliary cholangitis 2 cases of neoplasia were observed in our series, the first one was a marginal zone lymphoma and the second one was a pulmonary adenocarcinoma. 3 deaths were reported, one by pulmonary embolism, and the 2 patients who presented a neoplastic pathology. <h3>Conclusion</h3> Despite the small number of our patients, our results agree with those of the literature. The male sex seems to be associated with more severe forms with a shorter diagnostic delay, diffuse skin involvement, severe Raynaud's phenomenon, and early and severe pulmonary involvement. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
AB1152 FATIGUE IN PATIENTS WITH PSORIATIC ARTHRITIS OF EMPLOYABLE AGE
Authors: N. Тileubek, I. Fairushina, D. Abdulganieva, E. Kirillova
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Fatigue is an important and underrated multifactorial manifestation of psoriatic arthritis (PsA). <h3>Objectives</h3> The evaluation of frequency and relationship of fatigue with anthropometric, clinical, laboratory, ultrasound (US) data and quality of life (QoL) in patients with PsA of employable age. <h3>Methods</h3> The study included 92 patients with PsA aged 18-59 years. Assessment of fatigue was conducted using a fatigue subscale from the FACIT-F questionnaire. Severity of skin lesions and arthritis was determined with PASI and DAPSA, respectively, as well as anthropometric data, the number of painful and swollen joints and entheses, inflammatory biomarkers, the number of inflamed entheses and entheses with structural changes and the number of active and non-active synovitis detected by US, QoL by SF-36 and DLQI and functionality by HAQ-DI. <h3>Results</h3> In all 92 patients: male - 42 (45.7%), mean age 42.9±9.6 (SD) years (y), PsA duration was 7 (2; 11.8) y, DAPSA 15.2 (10.2; 21.4), PASI 3,8 (1,2; 9,6). Fatigue (FACIT-F values &lt;34 points) was detected in 46 (50%) patients. It was associated with psoriasis (p&lt;0.05) and PsA duration (p&lt;0.01), DAPSA (p&lt;0.01), and clinical enthesitis (p&lt;0.01). At the same time, there was no relation between (b/w) age and anthropometric data (body mass index, waist and hip circumference, waist-to-hip ratio) (p&gt;0.05). FACIT-F score was correlated with physical functioning (SF-36 subscale) and DLQI scores (p&lt;0.01). These data are consistent with findings from other studies, especially with psoriasis burden, despite the fact that the relation b/w fatigue, PASI and psoriatic onychodystrophy (NAPSI) was not found (p&gt;0.05). Association of fatigue with inflammatory markers (ESR, hs-CRP) and US articular and entheseal inflammation was not found (p&gt;0.05). Probably this indicates a greater influence of clinical signs, rather than US that could be explained by the high incidence of asymptomatic course of these changes. <h3>Conclusion</h3> Fatigue was found in 46% of employable aged PsA patients and was associated with clinical signs of PsA, particularly, with its activity and duration. Fatigue has been linked to physical functioning and DLQI scores. Further research is needed to investigate the individual factors that make the greatest influence to the fatigue development. The results of this study may indicate the need for routine fatigue examination among people with active PsA. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.